Abbott Labs (ABT) is a consistent performer with diversified healthcare operations, including pharmaceuticals, diagnostics, medical nutrition products, and medical devices/stents. ABT is back to the lower end of its trading range near 50 bucks, presenting an excellent entry point with a 2.8% dividend yield and forward PE of about 14X.
Celgene (CELG) is also trading at the low end of its trading range around 50 bucks as a large-cap growth stock focused on cancer biotech products and research with an estimated PEG ratio below one.
The accompanying table [click to enlarge or download] presents the top five rated companies with market caps of at least $250M from each of the 10 new healthcare indexes developed by ETF Innovators [ETFI] from a database of about 500 companies worldwide. The ETFI Global Healthcare Sector PerformIdex consists of 50 top rated companies on an equal weight basis from each of the 10 new healthcare indexes as an alternative strategy to existing health composite ETFs with highly correlated returns and over-weight exposure to th
The accompanying table includes 47 U.S.-listed companies with market caps over $10B and dividend yields over 5%, excluding all companies from the following sectors or industry groups: finance, insurance, consumer cyclical products, retailers, and basic materials. Also, the following dividend ETFs are included in the table as a comparison:
1.) iShares Dow Jones Select Dividend (DVY) 2.) WisdomTree Dividend Top 100 (DTN) 3.) SPDR S&P Dividend ETF (SDY) 4.) PowerShares High Yield Dividend Achievers (PEY)
"We are seeing quality names at fire-sale prices, and I think you must take advantage of that," says income expert Nilus Mattive in Dividend Superstars. Here's a trio of favorites.
"Pfizer (NYSE: PFE) recently reported great third-quarter results. The company tripled its profits from the same period a year ago. While last year's results were hurt by a one-time charge, Pfizer is obviously seeing continued demand for most of its drugs.
The accompanying table contains a summary and statistics for 16 ETFI global equity indexes and two commodity pool fund ideas, with the short/inverse and defensive themes outpacing the overall market averages over the past year in the midst of ongoing market turmoil around the world.
Although currently out of favor with investors, new commodity pool fund ideas include timber and coal. The CoalFund is a commodity pool that is structured to track the performance of exchange-traded, near-month futures contracts
The accompanying table presents my 60 defensive growth stock picks at the recently launched online investing site Inner8.com , which I wrote about yesterday. My picks are focused on healthcare and consumer staples, along with some cash rich tech companies such as Microsoft (MSFT). My picks include companies across the entire spectrum of market cap and risk in the biotech industry, ranging from top performers such as Amgen (AMGN) and Celgene (CELG) to small and micro-cap picks such as Discovery Labs (DSCO),
It is amazing what bargains are out there today Pfizer Inc. is only one of them and I am adding it to my portfolio. A nice dividend with options to sell and in a business that can only keep growing.
Pfizer, Inc. engages in the discovery, development, manufacture, and marketing of prescription medicines for humans and animals worldwide.
Despite the notion of investing in the healthcare sector as a safe haven, the following six companies (APPY, CMED, CYPB, DSCO, MYL, PFE) are all down sharply over the past year despite solid underlying fundamentals, which are largely unaffected by global economic conditions.
Diagnostics
China Medical (CMED) is trading near its IPO levels of August 2005 despite excellent growth prospects and a PEG ratio of 0.3X, a forward PE of 8X, and a dividend yield of 1.8%. For some perspective on the velocity of the downturn in CMED, the stock
Pfizer (PFE) posted an EPS of $0.62 on revenues of just under $12B, which was two cents ahead of consensus earnings estimates and in-line with revenue estimates for the quarter. The Company raised its full-year revenue view to $48-$49B while narrowing its earnings estimate to a range of $2.36-$2.41 per share. Pfizer also raised its 2008 cost reduction target to at least $2B. International sales posted gains of 13% (mainly due to a currency exchange benefit of 10%) compared to a decline in U.S. revenues of 15% from the yea
As I have written previously on Pfizer (PFE), I continue to recommend shares of the Company as a turnaround play around the $15 per share level, which equates to an even fatter dividend yield of 8.5% since I first wrote about the stock in July trading two bucks higher before the market meltdown occurred. Despite significant patent challenges to Lipitor and other products in Pfizer’s portfolio over the next few years, the Company’s strong balance sheet, marketing muscle, and ability to bolster its pipeline through targeted acquisitions should
The accompanying table presents a 20-stock defensive growth portfolio which I believe will outperform the overall market as measured by the S&P 500 Index as the current panic trade comes to an end and investors stop selling stocks regardless of their fundamentals. The average PEG ratio for this group of stocks is below one and the average dividend yield of 4.4% is nearly two times the S&P 500 ETF (SPY) yield of 2.4%. All of the stocks have a market cap over $1B with an average of just under $75B and the indust
ImClone Systems (IMCL) is set to sell itself for $6.1B or about $70 per share to the mystery big pharma bidder that Chairman Carl Icahn introduced as a defense against Bristol-Myers (BMY) original offer of $60, which was recently upped to $62 per share for the remaining 83% stake it does not already own. I have written about the saga on my blog since the end of July when Bristol-Myers made the original offer, but the Wall Street Journal s reporting the most likely bidders are Pfizer (PFE) or Eli Lilly (LLY).
Both of these big pharmas are in need of a pipeline and have the cash to...
The accompanying table presents a full FDA calendar of decision dates updated through today, which I will maintain at the bottom of my blog in place of the previous Global Carbon Trading Index. Click on the calendar image above or on my blog to view or download the PDF version of the FDA calendar, which I will also maintain at: www.geocities.com/mikehavrx/fdac.pdf .
Several key decisions are pending through the end of this month for the group of 14 big pharma companies I outlined yesterday, including Eli Lilly (L
The accompanying table presents an overview of big pharma companies, presented in descending order by market cap. My favorite play in the space remains to be Pfizer (PFE), which I have written about previously and finally bought shares today at $17.90 with a dividend yield exceeding 7%. Despite growth concerns and looming generic competition for Lipitor in late 2011, I bought shares of Pfizer today as a value pick and turnaround play which operates in a defensive sector with a strong balance sheet. Also, the Company is aggressive
ImClone Systems (IMCL) has rejected an unsolicited $60 per share bid from U.S. Erbitux marketing partner Bristol-Myers (BMY) made at the end of July and announced today that it has received an offer from an unidentified big pharma company for $70 per share in cash. ImClone has received the formal offer and will allow two weeks for the bidding company to conduct due diligence. ImClone Chairman and prominent activist investor Carl Icahn has been in talks with the CEO of the pharmaceutical company which made the new of
3 Clean Energy Stocks For An Obama Presidency
- How will the stock markets respond to a new US president? Martin Delholm says the impact will be less than some people expect. But some sectors will be...
Portfolio results thru 8/8/08
- Portfolio at www.updown.com - started 1/11/08
9.8% return includes dividends and commission.
Started socialpicks on 6/30. some stocks here are not in...
Stock update and watch list 7/29/08
- Due to difficulties understanding the socialpicks system regarding changing rating from buy to hold and thus resetting the performance, I wanted to sum...